10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Sunday, June 7, 2009

Elder Pharmaceuticals Ltd:-Future growth outlook and prospects

Scripscan:Elder Pharmaceuticals Ltd
Traded in:Nse-bse

Story:Elder Pharma commenced operations in 1988, and is engaged in manufacture of drug formulations in the therapeutic areas of woman healthcare, wound management and nutraceuticals. It also manufactures APIs and generic drugs in small quantities. Elder Pharma is a mid-sized player which follows the non-infringing business model of either in-licensing products of innovator companies or manufacturing off-patented drugs. It has entered into marketing and manufacturing alliances with 28 international companies to launch their research-based products in India. It has been successful in building its brands in niche categories. Elder Pharma is the market leader in calcium supplements, wound healing and injectable B12 vitamin. The company''s top five brands contribute 44% to its total sales. Over 95% of its revenues are generated from the domestic market.The company plans to grow organically, as well as inorganically. While it is aggressively marketing its existing products to new markets, it is also enlarging its presence in more therapeutic areas by launching new products. In August ''07, Elder Pharma acquired 20% in UK-based NeutraHealth for around Rs 47 crore, giving it access to the latter''s multiple brands. The company is also completing the acquisition of Bulgaria-based Biomeda, which will enable it to increase its revenues by around Rs 120 crore per year from the present fiscal. Elder Pharma has recently added new manufacturing facilities and plans to commission new units. It is also focusing on contract manufacturing, primarily through its alliance partners. Exports currently account for just 4-5% of its total revenues. The company plans to ramp up its exports by targeting semi-regulated markets. It also aims to enhance the share of APIs in its total turnover to 20% by FY10, from 8% currently.It has an average dividend payout of 19% (average of the past five years). The company expects to maintain its payouts at 20-25% of its profits in future. Elder Pharma trades at an EPS of Rs 39.5. On the back of its capacity expansion, increased product profile and expanding global footprint, it plans to grow 30% y-o-y to achieve a turnover of Rs 1,000 crore by ''10. Considering estimated earnings for FY10, the company is currently trading at forward P/Es of 4,.A ROBUST healthcare sector has accelerated the growth of fast moving health goods (FMHG) in India. And Elder Pharma, which has an eclectic bunch of offerings, is cashing in on the good times. The company has just the right mix of drug formulations, FMHG and active pharma ingredients (APIs) and is an attractive pick for investors who want to capture growth in the defensive sector.A great buy at lower levels.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner